Potential role of short-chain fatty acids in the pathogenesis and management of acute lymphocytic leukemia.

4区 医学 Annals of translational medicine Pub Date : 2024-08-01 Epub Date: 2023-11-30 DOI:10.21037/atm-23-1806
Yajing Song, Peter Gyarmati
{"title":"Potential role of short-chain fatty acids in the pathogenesis and management of acute lymphocytic leukemia.","authors":"Yajing Song, Peter Gyarmati","doi":"10.21037/atm-23-1806","DOIUrl":null,"url":null,"abstract":"<p><p>Acute lymphocytic leukemia (ALL) is an aggressive hematological malignancy of highly proliferative lymphoblasts. ALL is the most common cancer in children, and is typically treated with combination chemotherapy. The 5-year survival of ALL improved significantly in recent decades with this treatment approach. However, certain age groups (below 2 and over 10 years of age) have much worse prognosis, and over 50% of patients with ALL experience long-term side effects proportional to the dosage of anticancer drugs. Therefore, different treatment strategies are required to improve survival in ALL and to reduce side effects of chemotherapy. Since epigenetic modifications are dominantly reversible, \"epidrugs\" (drugs targeting epigenetic markers) are considered for feasibility in the treatment of ALL as epigenetic modifications, and acetylation of histones was demonstrated to play a critical role in the pathogenesis of ALL. Histone deacetylases (HDACs) have been shown to be differentially expressed in several hematological malignancies, including ALL. HDAC inhibitors (HDACis) have been shown to express selective toxicity for ALL cells, but they showed limited efficacy and higher than expected toxicity in mouse models or clinical trials in ALL. The aim of this review is to examine the role of the microbiota and microbial metabolites in the mechanisms of HDAC functions, and explore the utilization of the microbiota and microbial metabolites in improving the efficacy of HDACi in ALL. HDAC regulators and natural HDACi are depleted in ALL due to microbiota change leading to a decrease in butyrate and propionate, and HDACi treatment is not effective in ALL due to their short half-life. We propose that HDACi released by the microbiota may be necessary in HDAC regulation and this process is impaired in ALL. Furthermore, the review will also consider the role of restoration of the microbiota or supplementation of natural HDACi in potentially restoring HDAC and HDACi functions.</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"12 4","pages":"74"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11304434/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of translational medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/atm-23-1806","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Acute lymphocytic leukemia (ALL) is an aggressive hematological malignancy of highly proliferative lymphoblasts. ALL is the most common cancer in children, and is typically treated with combination chemotherapy. The 5-year survival of ALL improved significantly in recent decades with this treatment approach. However, certain age groups (below 2 and over 10 years of age) have much worse prognosis, and over 50% of patients with ALL experience long-term side effects proportional to the dosage of anticancer drugs. Therefore, different treatment strategies are required to improve survival in ALL and to reduce side effects of chemotherapy. Since epigenetic modifications are dominantly reversible, "epidrugs" (drugs targeting epigenetic markers) are considered for feasibility in the treatment of ALL as epigenetic modifications, and acetylation of histones was demonstrated to play a critical role in the pathogenesis of ALL. Histone deacetylases (HDACs) have been shown to be differentially expressed in several hematological malignancies, including ALL. HDAC inhibitors (HDACis) have been shown to express selective toxicity for ALL cells, but they showed limited efficacy and higher than expected toxicity in mouse models or clinical trials in ALL. The aim of this review is to examine the role of the microbiota and microbial metabolites in the mechanisms of HDAC functions, and explore the utilization of the microbiota and microbial metabolites in improving the efficacy of HDACi in ALL. HDAC regulators and natural HDACi are depleted in ALL due to microbiota change leading to a decrease in butyrate and propionate, and HDACi treatment is not effective in ALL due to their short half-life. We propose that HDACi released by the microbiota may be necessary in HDAC regulation and this process is impaired in ALL. Furthermore, the review will also consider the role of restoration of the microbiota or supplementation of natural HDACi in potentially restoring HDAC and HDACi functions.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
短链脂肪酸在急性淋巴细胞白血病的发病机制和治疗中的潜在作用。
急性淋巴细胞白血病(ALL)是一种由高度增殖的淋巴母细胞引起的侵袭性血液恶性肿瘤。急性淋巴细胞白血病是儿童最常见的癌症,通常采用联合化疗进行治疗。近几十年来,通过这种治疗方法,ALL 的 5 年生存率显著提高。然而,某些年龄组(2 岁以下和 10 岁以上)的预后更差,50% 以上的 ALL 患者会出现与抗癌药物剂量成正比的长期副作用。因此,需要采取不同的治疗策略来提高 ALL 患者的生存率并减少化疗的副作用。由于表观遗传修饰主要是可逆的,因此 "表观药物"(针对表观遗传标记的药物)被认为是治疗 ALL 表观遗传修饰的可行方法,组蛋白的乙酰化被证明在 ALL 的发病机制中起着关键作用。组蛋白去乙酰化酶(HDACs)在包括 ALL 在内的多种血液恶性肿瘤中均有不同程度的表达。HDAC抑制剂(HDACis)已被证明对ALL细胞具有选择性毒性,但在ALL小鼠模型或临床试验中显示出有限的疗效和高于预期的毒性。本综述旨在研究微生物群和微生物代谢物在 HDAC 功能机制中的作用,并探讨如何利用微生物群和微生物代谢物提高 HDACi 在 ALL 中的疗效。由于微生物群变化导致丁酸盐和丙酸盐减少,HDAC调节剂和天然HDACi在ALL中被耗尽,而HDACi由于半衰期短,在ALL中治疗效果不佳。我们认为,微生物群释放的 HDACi 可能是 HDAC 调节所必需的,而这一过程在 ALL 中受损。此外,本综述还将考虑恢复微生物群或补充天然 HDACi 对恢复 HDAC 和 HDACi 功能的潜在作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
769
期刊介绍: The Annals of Translational Medicine (Ann Transl Med; ATM; Print ISSN 2305-5839; Online ISSN 2305-5847) is an international, peer-reviewed Open Access journal featuring original and observational investigations in the broad fields of laboratory, clinical, and public health research, aiming to provide practical up-to-date information in significant research from all subspecialties of medicine and to broaden the readers’ vision and horizon from bench to bed and bed to bench. It is published quarterly (April 2013- Dec. 2013), monthly (Jan. 2014 - Feb. 2015), biweekly (March 2015-) and openly distributed worldwide. Annals of Translational Medicine is indexed in PubMed in Sept 2014 and in SCIE in 2018. Specific areas of interest include, but not limited to, multimodality therapy, epidemiology, biomarkers, imaging, biology, pathology, and technical advances related to medicine. Submissions describing preclinical research with potential for application to human disease, and studies describing research obtained from preliminary human experimentation with potential to further the understanding of biological mechanism underlying disease are encouraged. Also warmly welcome are studies describing public health research pertinent to clinic, disease diagnosis and prevention, or healthcare policy.
 With a focus on interdisciplinary academic cooperation, ATM aims to expedite the translation of scientific discovery into new or improved standards of management and health outcomes practice.
期刊最新文献
Comparing surgical techniques and results of secondary ischemic mitral regurgitation: a state-of-the-art literature review. Association between sore throat and early immune responses against COVID-19 before and after the emergence of the Omicron variant. Cardiovascular handgrip responses during treadmill exercise: randomized pilot trial. Characterization of the single cell landscape in normal and osteoarthritic equine joints. Emergency tracheostomy management in critical care and the operating room.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1